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Introduction
Targeting the RAS oncoproteins remains unfulfilled in the clinic. 
Although a newly developed KRASG12C inhibitor has achieved 
considerable success in lung cancer (1), it is ineffective in other 
KRASG12C-mutant cancer types such as colon cancer. In addition, 
HRAS, NRAS, and non-G12C KRAS oncoproteins remain undrug-
gable. In pancreatic ductal adenocarcinoma (PDAC), though 
KRAS mutations are virtually universal, the G12C mutation is rare 
(2). Strategies to target KRAS effectors including the mitogen- 
activated protein kinase (MAPK) and phosphoinositide 3-kinase 
(PI3K) cascades are unsuccessful (3) and multiple resistance 
mechanisms have been described explaining their failures. Aber-
rant activation of the NF-κB transcription factors, especially the 
RELA (or p65) family member, occurs in approximately two-thirds 
of PDAC and is a major mechanism that underlies the aggressive 
nature of PDAC (4–7). In a genetically-engineered mouse model 
(GEMM), ablation of IKKβ kinase, which activates the NF-κB 
members, completely abolished KRASG12D-induced PDAC devel-
opment (8). However, development of IKK inhibitors is hampered 
by clinical toxicities and off-target effects (9). PDAC cells and the 
surrounding stromal fibroblasts secrete IL-1β that engages inter-
leukin-1 receptor–associated kinase 4 (IRAK4) to drive IKKβ and 
the NF-κB pathway (10), indicating that IRAK4 is a promising ther-
apeutic target. IRAK4 is a critical signal transducer downstream 
of the innate immune receptors including the Toll-like (TLR) and 
IL-1 (IL-1R) receptors (11). When engaged, these receptors recruit 
MYD88 and IRAK1 as adaptors, forming a platform that recruits 
IRAK4. IRAK4 then activates the IKK complex, allowing cyto-
plasmic NF-κB subunits such as RELA/p65 and p50 to enter the 
nucleus and transactivate inflammatory and survival genes (12). 
The protumorigenic role of this pathway has been described in 
melanoma (13), breast (14), head and neck (15), colon (16), and 
pancreatic cancers (7, 10). However, these studies do not describe 
the genetic context in which IRAK4 inhibition is most likely to 
succeed, nor do they provide insights into the crosstalk of IRAK4 
signaling with other oncogenic events besides the NF-κB pathway.
In this study, we interrogated The Cancer Genome Atlas 
(TCGA) database and found that MYD88, IRAK1, and IRAK4 are 
associated with RELA expression and poor prognosis in PDAC. 
We further found that IRAK4 is essential for RAS-induced onco-
genic transformation. Interestingly, by unbiased reverse-phase 
protein array (RPPA) and RNA sequencing we discovered signaling 
crosstalk between IRAK4 and the MAPK pathway in KRAS-mutant 
PDAC cells. We elucidate the mechanism of how oncogenic KRAS 
activates IRAK4, and uncover tumor progression locus 2 (TPL2, 
also known as MAP3K8 or COT) as the essential kinase that con-
trols both MAPK and NF-κB cascades downstream of IRAK4 and 
effectively KRAS. In addition, we interrogate the role of TPL2 
under genotoxic stress and show that a TPL2 inhibitor (TPL2i) 
synergizes with the FIRINOX chemotherapy regimen to suppress 
human and murine in vivo PDAC growth. Last, we screened recur-
rent MAP3K8 mutations from TCGA and discovered 2 gain-of-
NF-κB transcription factors, driven by the IRAK/IKK cascade, confer treatment resistance in pancreatic ductal adenocarcinoma 
(PDAC), a cancer characterized by near-universal KRAS mutation. Through reverse-phase protein array and RNA sequencing 
we discovered that IRAK4 also contributes substantially to MAPK activation in KRAS-mutant PDAC. IRAK4 ablation 
completely blocked RAS-induced transformation of human and murine cells. Mechanistically, expression of mutant KRAS 
stimulated an inflammatory, autocrine IL-1β signaling loop that activated IRAK4 and the MAPK pathway. Downstream of 
IRAK4, we uncovered TPL2 (also known as MAP3K8 or COT) as the essential kinase that propels both MAPK and NF-κB 
cascades. Inhibition of TPL2 blocked both MAPK and NF-κB signaling, and suppressed KRAS-mutant cell growth. To counter 
chemotherapy-induced genotoxic stress, PDAC cells upregulated TLR9, which activated prosurvival IRAK4/TPL2 signaling. 
Accordingly, a TPL2 inhibitor synergized with chemotherapy to curb PDAC growth in vivo. Finally, from TCGA we characterized 
2 MAP3K8 point mutations that hyperactivate MAPK and NF-κB cascades by impeding TPL2 protein degradation. Cancer cell 
lines naturally harboring these MAP3K8 mutations are strikingly sensitive to TPL2 inhibition, underscoring the need to identify 
these potentially targetable mutations in patients. Overall, our study establishes TPL2 as a promising therapeutic target in 
RAS- and MAP3K8-mutant cancers and strongly prompts development of TPL2 inhibitors for preclinical and clinical studies.
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inhibitory IκB genes (NFKBIE and NFKBIB), RELB, NFKB2, 
IRAK1, and MYD88. Of these, MYD88 and IRAK1 caught our 
attention because these are known upstream activators of the 
IKK kinases (20, 21). MYD88 and IRAK1 expression positively 
correlated with each other (Supplemental Figure 1C) and RELA 
(Supplemental Figure 1D). Notably, patients with high (Z score 
> 1.0) MYD88 and/or IRAK1 expression (termed “MYD88High, 
IRAK1High”) had significantly worse progression-free survival 
(log-rank P = 0.0020, Figure 1D), disease-free status (Figure 1E), 
overall survival (log-rank P = 0.0147, Figure 1F), and vital status 
at the time of data cutoff (Figure 1G), compared with patients 
with low (Z score < 1.0) MYD88 and/or IRAK1 expression (termed 
“MYD88Low, IRAK1Low”). Together, these results demonstrate 
positive correlation between MYD88-IRAK and RELA expres-
sion, and further support the TLR/IL-1R canonical pathway as 
the main driving mechanism of NF-κB activity in PDAC that 
translates into clinical aggressiveness, congruent with published 
studies (7, 8, 10, 22).
Unlike MYD88 and IRAK1, which function as adaptor proteins, 
IRAK4 is the bone fide kinase that initiates NF-κB signaling and 
can be targeted (7, 20). Phosphoactivation of IRAK4 is associated 
with higher RELA activity and poor survival of PDAC patients (7). 
IRAK4, though not included in the predefined 37-gene MSigDB 
NF-κB signature, was significantly overexpressed in PDAC com-
pared with normal pancreas (Figure 1H). Analysis of the whole 
TCGA data showed significantly higher IRAK4 expression in 
PDAC compared with majority of other cancers (Supplemental 
Figure 1E and Supplemental Table 1), supporting a pathogenic role 
of IRAK4 in PDAC.
Both IRAK4 and KRAS can drive NF-κB signaling in PDAC, 
but their crosstalk has not been investigated. While KRAS oncop-
rotein can stimulate the noncanonical IKK through the RalGEF/
RalB/TBK1 effector (23) and the canonical IKKα/β through the 
PI3K/AKT/mTOR effectors (24), IRAK4 uses TAK1 kinase to 
activate IKKβ (12). Therefore, IRAK4 should not be required for 
KRAS-induced oncogenesis per se. Yet, to test this, we stably 
expressed pairs of oncogenes including c-MYCT58A and HRASG12V, 
SV-40 T/t antigens and HRASG12V, or SV-40 T/t and KRASG12V in 
WT and Irak4–/– murine embryonic fibroblasts (MEFs). Surpris-
ingly, anchorage-independent (AI) growth in soft agar, a classical 
assay for transformation, is completely abrogated in IRAK4–/– 
MEFs, but this could be fully rescued with reexpression of murine 
Irak4 cDNA (Figure 1I). Consistently, Irak4–/– MEFs expressing 
oncogenic HRAS or KRAS failed to form tumors in nude mice (Fig-
ure 1J). As further confirmation, we employed the CRISPR/Cas9 
technique to ablate IRAK4 in 3 KRAS-transformed cell lines: KP2 
(a murine PDAC line originating from a p48-Cre; Tp53fl/WT; LSL-
KrasG12D, or KPC mouse), a human embryonic kidney (HEK T/tH) 
line transformed with hTERT, SV-40 T/t, and KRASG12V, and the 
KRASG12D-mutant PANC-1 line. Again, loss of IRAK4 completely 
abrogated tumorigenic growth of these lines in nude mice (Figure 
1J). KP2 cells expressing single guide RNAs against Irak4 (sgIrak4) 
were severely impaired not only in AI growth, but also 2-dimen-
sional (2D) proliferation (Figure 1K and Supplemental Figure 1F), 
revealing a role of IRAK4 in cell fitness. Similarly, AI growth of 
KP2 cells was dose-dependently suppressed by PF06650833 (25), 
a selective IRAK4 inhibitor (IRAK4i) Figure 1L). To dissect the role 
function point mutants, which naturally exist in ovarian cancer and 
melanoma cell lines, and are highly sensitive to TPL2 blockade.
Results
IRAK signaling dictates NF-κB activity in PDAC and is essential for 
RAS oncogenesis. Aberrant NF-κB activation is conventionally 
defined by increased RELA (or p65 NF-κB family member) expres-
sion or nuclear translocation by immunohistochemistry (IHC) 
in tumor samples (17, 18). To more comprehensively understand 
the NF-κB–associated transcriptomes in PDAC, we evaluated 
the expression pattern of 37 core NF-κB genes, which include 
RELA as defined by the Molecular Signatures Database (MSigDB) 
(19), in PDAC samples from TCGA (Firehose Legacy, n = 185). By 
unsupervised clustering we observed heterogeneous expression 
of these 37 genes across all samples, reflecting the complexity of 
mechanisms that activate NF-κB and presence of different cat-
egories of NF-κB signatures in PDAC (Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI137660DS1). Because RELA expression is the 
single, most established NF-κB marker associated with poor prog-
nosis in PDAC, we divided these samples into 3 groups based on 
RELA mRNA level: RELAHigh (Z score > 1.0, n = 29), RELAMed (Z 
score between –1.0 and 1.0, n = 129), and RELALow (Z score < –1.0, 
n = 29) (Figure 1A). Compared with the RELALow group, patients 
in the RELAHigh and RELAMed groups had significantly worse 
progression-free and overall survival (Figure 1B and Supplemen-
tal Figure 1B). We focused our analysis on RELAHigh and RELALow 
cohorts in order to discern the remaining NF-κB genes that clus-
ter with RELA expression. Notably, many genes in the canonical 
NF-κB pathway were upregulated in the RELAHigh group (Figure 
1C), such as the IKK isoform genes (IKBKB, IKBKE, and IKBKG), 
Figure 1. IRAK signaling dictates NF-κB activity in PDAC and is essential 
for RAS oncogenesis. (A) Classification of patients with low, medium,  
and high RELA expression based on mRNA Z score from TCGA. (B) Pro-
gression-free survival (PFS) and overall survival (OS) of PDAC patients with 
high versus low RELA expression. (C) Heatmap comparing mRNA expres-
sion of NF-κB signature genes from the Broad Institute Molecular  
Signatures Database (gene sets are listed in Supplemental Table 3) in 
RELAHigh vs. RELALow patients. (D and E) PFS and disease-free status, 
respectively, of PDAC patients with high MYD88 and/or high IRAK1 
expression (“MYD88High, IRAK1High”) versus low MYD88 and/or low IRAK1 
expression (“MYD88Low, IRAK1Low”). Eight patients overlapping between 2 
groups were excluded. (F and G) OS and vital status of patients as in D and 
E. (H) Graph of IRAK4 expression in normal human pancreas versus PDAC. 
Data for normal tissue is from the Genotype-Tissue Expression (GTEx) 
project and PDAC expression from TCGA PanCancer Atlas. P values are 
from unpaired 2-sided t test. (I) Soft-agar colonies formed by Irak4-KO and 
rescue (KO + Irak4WT) MEF cells transformed with 3 pairs of oncogenes. Data 
show 9 replicates from 3 independent experiments. (J) Number of tumors 
formed in nude mice from subcutaneous implantation of WT and IRAK4-
KO human and murine RAS-mutant and/or PDAC cell lines. n = 8 tumors 
per condition. (K) Quantification of soft-agar colonies formed by WT versus 
Irak4-KO KP2 cells. Data show 6 replicates from 2 independent experi-
ments. (L) Soft-agar colonies formed by KP2 cells treated with IRAK4i  
or vehicle (V). (M) Soft-agar colonies formed by WT and KRASG12D HPNE 
cells ectopically expressing WT IRAK4 and treated with IRAK4i. For L and 
M, 3 independent experiments were performed, each in technical triplicate, 
and one set of data is shown. All error bars indicate mean ± SEM. ****P < 
0.0001; ***P < 0.0002; **P < 0.0021; *P < 0.0332.
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firmation, Western blots showed reduced p-MEK and p-ERK levels 
in IRAK4-ablated KP2 cells (Figure 2E). Various NF-κB signatures 
were also similarly affected (Supplemental Figure 2C). Gene set 
enrichment analysis (GSEA) showed oncogenic KRAS signaling 
and PDAC signatures to be significantly downregulated following 
Irak4 ablation and restored in Irak4-rescued cells (Figure 2, F–H). 
In accordance, IRAK4i dose-dependently suppressed MAPK activ-
ity in 2 murine PDAC lines, KP2 and KI (derived from a PDX1-Cre; 
INK4afl/fl; LSL-KRASG12D mouse), as well as KRAS-mutant PDAC 
patient–derived cell lines (PDCLs) Pa01C, Pa02C, and Pa03C, 
and a conventional human pancreatic adenocarcinoma cell line, 
HPAC (Figure 2, I and J, and Supplemental Figure 2D). As fur-
ther confirmation, IRAK4i dose-dependently reduced serum-re-
sponse element–driven (SRE-driven) luciferase reporter activity in 
HPAC cells (Supplemental Figure 2E) and viability of various KRAS- 
mutant PDAC lines in vitro (Supplemental Figure 2F). To clearly 
establish the role of IRAK4 in KRAS-induced MAPK signaling, we 
used 2 isogenic pairs of cell lines expressing empty vector, KRASG12D 
(for HPNE), or KRASG12V (for 293T). As expected, expression of 
KRAS mutants clearly upregulated p-MEK, p-ERK, and p-RSK 
levels, but all these were dose-dependently blocked by IRAK4i (Fig-
ure 2K). Importantly, expression of an activated MEK mutant (MEK1-
5DD) rendered HEK T/tH–KRASG12V cells approximately 3-fold less 
sensitive to growth inhibition by IRAK4i (Supplemental Figure 2G), 
positioning IRAK4 upstream of MEK. Besides the MAPK pathway, 
IRAK4i also suppresses p-p105 levels in Pa01C, Pa02C, Pa03C, and 
HPAC cells (Figure 2J and Supplemental Figure 2D), resonating with 
previous findings that IRAK4 is a driver of the NF-κB pathway (7, 16). 
Intriguingly, we also observed dose-dependent suppression of SRE 
activity by IKK inhibitor IMD-0354 in HPAC, suggesting a contribu-
tion of IKK to MAPK activity in PDAC cells (Supplemental Figure 2E). 
Together, these results establish IRAK4 as a significant contributor to 
KRAS-induced MAPK signaling.
TPL2 mediates signaling between IRAK4 and the MAPK path-
way. Next, we investigated the mechanistic link between IRAK4 
and MEK. In myeloid cells, IL-1, TNF, or LPS activates MEK and 
ERK through engaging TPL2 kinase (or COT/MAP3K8) (26, 27). 
We therefore hypothesized that IRAK4 engages TPL2 to activate 
MEK and ERK. Indeed, ectopic expression of TPL2 in Pa01C and 
HPAC cells enhanced p-MEK and p-ERK levels, but this effect was 
blocked by IRAK4i. Notably, the ectopically expressed TPL2 pro-
tein existed in an activated state, as determined by an anti–p-TPL2 
antibody, and was dose-dependently deactivated by IRAK4i, con-
firming IRAK4 as the upstream activator of TPL2 (Figure 3A and 
Supplemental Figure 3A). In support, ectopic expression of IRAK4 
upregulated p-TPL2, p-MEK, and p-ERK in 293T cells (Figure 3B).
To strengthen the link between IRAK4, TPL2, and MEK, 
we next performed leading-edge analysis using 15 published 
TPL2-associated gene signatures from the Broad Institute 
MSigDB, including significantly downregulated MAPK-related 
GO signatures identified in Irak4-ablated KP2 cells (Supplemental 
Table 3). Ablation of Irak4 decreased TPL2 (encoded by MAP3K8) 
expression in the majority of gene sets, and importantly, low TPL2 
expression was closely associated and clustered with low MEK1 
expression (Figure 3C and Supplemental Figure 3B). These data 
position TPL2 as the signal transducer between IRAK4 and MEK 
in PDAC. In human PDAC lines, we observed strong, positive cor-
of IRAK4 in KRAS-mutant human PDAC, we resorted to the HPNE 
model, an artificial pancreatic ductal epithelial line immortalized 
with hTERT and HPV E6/E7. Stable expression of KRASG12D in this 
line (named HPNE-KRASG12D) completes the malignant transfor-
mation, enabling AI growth. We found that ectopic expression of 
IRAK4 doubled the AI growth of HPNE-KRASG12D cells but had 
no effect on the untransformed HPNE cells (Figure 1M). Nota-
bly, treatment with PF06650833 not only reversed the effect of 
IRAK4 overexpression, but also crippled the AI growth of HPNE-
KRASG12D. Together, these studies showed IRAK4 is essential for 
and cooperates with mutant RAS in oncogenic transformation.
IRAK4 is crucial for oncogenic RAS-driven MAPK signaling. 
To understand the mechanism by which IRAK4 promotes RAS- 
induced transformation, we first performed an unbiased RPPA on 
HPNE-KRASG12D cells stably expressing IRAK4 or empty vector. 
Compared with vector-expressing cells, IRAK4-overexpressing 
cells exhibited a greater than 2-fold increase in phosphorylated 
FAK (p-FAK), p-ERK, total FAK, and FoxM1, which was reversed 
by IRAK4i treatment (Figure 2A). Indeed, various MAPK target 
proteins were activated by IRAK4 overexpression and conversely 
suppressed by IRAK4i (Figure 2B). We observed similar changes 
with p-p65/RELA (Supplemental Figure 2A), resonating with our 
previous studies (7, 10). As confirmation, overexpression of WT, 
but not kinase-dead IRAK4, enhanced p-ERK in 293T cells, as 
determined by Western blotting (Figure 2C). Next, we performed 
RNA sequencing analysis on KP2 cells expressing vector, 2 dif-
ferent sgIrak4, or sgIrak4 followed by rescue with a murine Irak4 
cDNA (termed “rescue”; Supplemental Figure 2B). Consistent 
with our RPPA results, MAPK, ERK, and progrowth gene ontology 
(GO) signatures were significantly suppressed in Irak4-depleted 
KP2 cells and restored in Irak4-rescued cells (Figure 2D). As con-
Figure 2. IRAK4 is crucial for oncogenic RAS-driven MAPK signaling. 
(A) Linear fold-change for all targets evaluated by reverse-phase protein 
array (RPPA) performed on HPNE-KRASG12D overexpressing (OE) IRAK4  
and treated with IRAK4i. Targets with fold-change >2 upon IRAK4 
overexpression are identified. (B) Heatmap showing relative expression 
of ERK-regulated targets in RPPA shown in A. (C) Immunoblots of 293T 
cells transfected with AU1 epitope–tagged WT or kinase-dead IRAK4. (D) 
Heatmap depicting fold-change for MAPK-, RAS-, and cell growth–related 
Gene Ontology (GO) signatures upon Irak4 knockout (KO) and rescue (KO 
+ Irak4WT) in murine KP2 cells. Comparisons are KO vs. WT and rescue vs. 
KO. Signatures significantly (P < 0.05) depleted (blue) or enriched (red) 
are marked with an asterisk (*). (E) Immunoblots of WT and Irak4-KO 
KP2 cells. (F and G) Gene set enrichment plot and normalized enrichment 
scores (NES), respectively, for signatures associated with oncogenic KRAS 
in WT, Irak4-KO, and rescue KP2 cells, compared as in D. “Hallmark” and 
“C6: Oncogenic Signatures” databases were used. Negative NES indicates 
downregulation and signatures significantly (P < 0.05) depleted (blue) or 
enriched (red) are marked with an asterisk (*). (H) Gene set enrichment 
plot for PDAC signature in Irak4-KO and -rescue KP2 cells. PDAC signature 
gene list is provided in Supplemental Table 3. Barcode plots under curves 
in F and H depict the enrichment clustering for individual genes in the 
respective gene signatures interrogated for KO vs. WT (top barcode) and 
rescue vs. KO (bottom barcode) cells. (I) Immunoblots of KP2 and KI cells 
treated with IRAK4i (PF06650833) or vehicle (V) for 24 hours in serum-free 
condition. (J) Immunoblots of PDAC cells treated with IRAK4i for 16 hours. 
(K) Immunoblots of HPNE-KRASG12D and 293T-KRASG12V cells treated with 
IRAK4i for 24 hours in serum-free media. For D and F–H, RNA sequencing 
was performed on n = 2 independent samples for each condition.
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relation between the protein levels of TPL2 and p-ERK (Figure 3, 
D and E) by Western blotting. In human and murine PDAC tumor 
tissues, IHC analyses showed co-occurrence of p-ERK, TPL2, and 
p-IRAK4 staining in the neoplastic ductal epithelia, whereas these 
markers were largely absent in normal ductal epithelia (Figure 3F).
High TPL2 expression is poorly prognostic in PDAC. We next per-
formed IHC analyses on a panel of 313 PDAC tissue microarray 
(TMA) specimens and found strong, significantly positive correla-
tion of H-score, defined by staining area and intensities, between 
TPL2 and p-IRAK4 (r = 0.56, P < 0.0001; Figure 4, A and B, and 
Supplemental Figure 4, A and B). Notably, high TPL2 staining cor-
related with poor overall survival in PDAC patients based on Wil-
coxon’s P = 0.03, a statistic that gives more weight to early deaths, 
as typically seen with PDAC patients (Figure 4C). From TCGA and 
Genotype-Tissue Expression (GTEx) project databases, MAP3K8 
mRNA expression was significantly higher in PDAC compared 
with normal pancreas (Figure 4D) and a majority of other cancer 
types (Supplemental Figure 4C and Supplemental Table 2). Next, 
using the median overall survival of TCGA PDAC patients (~15.5 
months), we divided patients into 2 groups, short (<15.5 months 
overall survival, n = 92) and longer (≥ 15.5 months overall survival, 
n = 93) survivors (Figure 4E). The short survivors had significantly 
higher MAP3K8 expression (Figure 4F). Conversely, high MAP3K8 
expression (arbitrarily defined as Z score > 1, MAP3K8High, n = 22) 
is significantly associated with poorer overall survival compared 
with low MAP3K8 expression (Z score < 1, MAP3K8Low, n = 28; Fig-
ure 4G). Together, these complementary studies position TPL2 as 
the intermediate kinase between IRAK4 and MEK and signify its 
potential as a therapeutic target warranting further investigation.
TPL2 drives both MAPK and NF-κB signaling in PDAC From 
GSEA analysis we found MAP3K8High PDAC samples to be 
enriched for both KRAS and NF-κB signatures (Figure 5A), mir-
roring our findings with IRAK4 (Figure 2F) and congruous with 
a prior report which showed that TPL2 can phosphoactivate the 
p105 NF-κB factor (28). To determine if TPL2 controls MAPK 
and NF-κB signaling, we treated KRAS-mutant PDAC cells with 
4-[(3-chloro-4-fluorophenyl)amino]-6-[(3-pyridinylmethyl) 
amino]-1,7-naphthyridine-3-carbonitrile, a selective ATP-compet-
itive small-molecule TPL2i that can suppress LPS-induced TNF-α 
production in human monocytes (29). Treatment with TPL2i 
dose-dependently suppressed p-MEK and p-ERK levels in mul-
tiple KRAS-mutant PDAC lines except PANC-1 (Figure 5B), and 
in 293T cells expressing KRASG12V (Figure 5C), establishing TPL2 
as a contributor to KRAS-induced MAPK activity. Notably, TPL2i 
dose-dependently blocked p-MEK and p-ERK without affecting 
p-BRAF (Figure 5D), suggesting that TPL2i does not compromise 
KRAS-RAF interaction and TPL2 activates MEK independently 
of RAFs. Apart from MAPK, TPL2i also dose-dependently sup-
pressed p-p105, but this did not lead to increased p50 processing. 
Notably, TPL2i potently suppressed p-p65 at S276 in 3 out of 4 
cell lines, but not S536 (Figure 5, D and E), consistent with pub-
lished studies (30). Conversely, ectopic expression of TPL2 dose- 
dependently increased p-p105, p-MEK, and p-ERK levels in 293T 
cells (Supplemental Figure 5A). These results show that TPL2 con-
trols both MAPK and NF-κB cascades in PDAC.
Like the RAF kinases, TPL2 is a MAP3K that activates MEK. 
However, in RAS-mutant cells, BRAF inhibitors such as PLX-4720 
and dabrafenib paradoxically hyperactivate MAPK cascades, 
which we also observed in KRAS-mutant HPAC, MIA Paca-2, and 
Pa01C cells expressing an SRE-driven luciferase reporter (Fig-
ure 5F and Supplemental Figure 5, B and C). In contrast, TPL2i 
dose-dependently suppressed SRE reporter activity in all 3 cell 
lines to levels matching those of MEK and ERK inhibitors. Nota-
bly, the MEK inhibitor trametinib unexpectedly enhanced NF-κB 
reporter activity in PDAC cells, perhaps representing a resistance 
mechanism underlying the lack of clinical efficacy of MEK inhib-
itors. On the other hand, TPL2i and IRAK4i dose-dependently 
suppressed both SRE and NF-κB reporter activities in KRAS-mu-
tant PDAC cells (Supplemental Figure 5D). Notably, neither TPL2i 
nor IRAK4i suppressed p-MEK and p-ERK in 293T cells transfect-
ed with oncogenic BRAFV600E (Supplemental Figure 5E), or in a 
BxPc-3 PDAC line that harbors an in-frame gain-of-function BRAF 
mutation and WT KRAS (Supplemental Figure 5F), demonstrat-
ing IRAK4 and TPL2 as separate activators of MAPK, other than 
RAFs, downstream of KRAS.
Supporting an essential role of TPL2 in KRAS-induced trans-
formation, TPL2i dose-dependently suppressed 3-dimensional 
(3D) AI and 2D clonogenic growth of HPNE-KRASG12D cells, HEKT/
tH-KRASG12V cells, conventional PDAC lines, and PDCLs (Figure 
5G and Supplemental Figure 6A). Knockdown of TPL2 by shRNA 
(shMAP3K8) severely impaired HPAC and Pa01C cell prolifera-
tion (Figure 5H). The subpopulation that eventually grew again 
had only partial TPL2 knockdown but displayed reduced p-MEK, 
p-ERK, and p-p105 levels (Figure 5I) and were markedly impaired 
in 2D clonogenic growth (Figure 5J), and 3D growth as organoids 
or soft-agar colonies (Figure 5K and Supplemental Figure 6B). 
Together, these data establish a critical role for TPL2 in PDAC and 
KRAS signaling via supporting both NF-κB and MAPK pathways.
KRAS induces autocrine IL-1β inflammatory signaling to activate 
IRAK4 and TPL2. Next, we investigated the mechanism by which 
KRAS activates the IRAK4/TPL2 axis. IRAK4 and TPL2 are typ-
ically activated downstream of IL-1, TNF-α, and TLRs, and not 
directly by KRAS. On this assumption, we surveyed the expression 
of IL-1α/β, TNF-α/β, IL-1R, and all the TLRs by qRT-PCR of HEK 
T/tH cells expressing an empty vector or KRASG12V. Of all 16 tar-
gets, only IL1B mRNA was significantly upregulated (by ~10-fold) 
in KRASG12V-expressing cells compared with vector control (Figure 
Figure 3. TPL2 mediates signaling between IRAK4 and the MAPK path-
way. (A) Immunoblot of Pa01C cells overexpressing HA epitope–tagged 
TPL2 WT that were treated with IRAK4i or vehicle (V) for 6 hours in serum-
free condition. (B) Immunoblots of 293T cells transfected with WT IRAK4 
for 48 hours. (C) Leading-edge analysis performed using data generated by 
gene set enrichment analysis in order to identify alterations in individual 
genes within each gene set tested. Significantly downregulated (P < 0.05) 
gene signatures were analyzed and a clustered heatmap was generated. 
Section of heatmap depicting change in MAP3K8 (TPL2) and MAP2K1 
(MEK1) expression is shown with original clustering preserved. TPL2-asso-
ciated gene set list is provided in Supplemental Table 3. (D) Immunoblot of 
various commercially available and patient-derived (Pa01C–Pa16C) human 
PDAC cell lines and 1 normal human pancreatic cell line (HPNE). (E) Correla-
tion plot of p-ERK and TPL2 intensities for PDAC cell lines in D. Two-tailed 
Pearson correlation (r) analysis was performed. (F) Representative H&E 
and IHC images of human and murine normal pancreas and PDAC tissue 
for p-ERK, TPL2, and p-IRAK4. n = 6 sections per stain. Scale bars: 50 μm 
(for full image [×400 magnification]) and 10 μm (insets).
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Figure 4. High TPL2 expression is poorly prognostic in PDAC. (A) IHC images representing high and low staining H-scores for TPL2 and p-IRAK4 with and 
without HALO analysis markup. H-score = 3 × (% of strongly stained area) + 2 × (% of moderately stained area) + 1 × (% of weakly stained area). (B) Spear-
man (r) correlation plot of TPL2 and p-IRAK4 H-scores from tissue microarray (TMA) analysis of 313 tissue specimens from 157 PDAC patients, represented 
in A. (C) Kaplan-Meier plot comparing survival of patients with high vs. low TPL2 protein expression based on analysis of TMA above. Of the patients with 
survival data, those who died within 1 month of surgery were excluded from the analysis. (D) Graph depicting MAP3K8 (TPL2) expression in normal human 
pancreas versus PDAC tissue. Data for normal pancreas tissue is from the Genotype-Tissue Expression (GTEx) project and PDAC expression was from the 
pancreatic adenocarcinoma TCGA PanCancer Atlas study. P values are from unpaired, 2-sided t test. Outliers (5 in normal, 3 in PDAC) were removed by 
ROUT, Q = 0.1%. (E) Graph of overall survival (OS) of TCGA PDAC patients separated into short- and longer-surviving cohorts using median OS of approx-
imately 15.5 months. (F) Graph comparing MAP3K8 mRNA expression in longer- vs. short-surviving patients defined in E. P values are from unpaired, 
2-sided t test. All 178 (out of 185) TCGA PDAC samples with mRNA expression data were analyzed. (G) Graph comparing months of OS of patients with high 
(Z score > 1, n = 22) versus low (Z score < 1, n = 28) MAP3K8 expression based on analysis of TCGA Firehose Legacy data set. P values from Kruskal-Wallis 
test. ****P < 0.0001; ***P < 0.0002.
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among the multiple mechanisms that underlie de novo chemo-
resistance. To address this, we examined whether the IRAK4/
TPL2 axis contributes to chemotherapy-induced survival and 
resistance, which will help formulate a rational combinatorial 
regimen for in vivo testing. We treated PDAC cells with 5 chemo-
therapeutic agents (gemcitabine, paclitaxel, SN-38, 5-fluorouracil 
[5-FU], and oxaliplatin) commonly used in patient care. Of these 
agents, SN-38, an active metabolite of irinotecan, was the most 
potent in inducing p-ERK, p-MEK, p-RSK, and notably p-TPL2 
and p-IRAK4, across multiple PDAC lines (Figure 7A and Supple-
mental Figure 9A), suggesting IRAK4 and TPL2 may contribute 
to MAPK activation following genotoxic stress. NF-κB was also 
induced, as evident by an increase in p-p105.
To determine the mechanism that activates these markers, 
we treated HPAC cells with gemcitabine/paclitaxel or FIRINOX 
(5-FU/SN-38/oxaliplatin), which mimic clinical regimens, and 
surveyed changes in expression of the TLRs and IL-1α/β in HPAC 
cells. Intriguingly, we observed significantly upregulated expres-
sion of TLR6, TLR9, and IL1A, but not IL1B, upon exposure 
to either chemotherapy (Figure 7B). Survey of 2 other PDCLs, 
Pa01C and Pa03C, showed TLR9 to be the only gene consistently 
upregulated following FIRINOX treatment (Figure 7C). Impor-
tantly, signaling from TLR9 is transmitted exclusively through 
IRAK4 (33). Indeed, proximity ligation assay showed markedly 
increased TLR9 and p-IRAK4 interaction following treatment of 
3 different PDAC lines with SN-38 (Figure 7D), suggesting TLR9 
to be the driver of IRAK4 and TPL2 upon chemotherapy expo-
sure. Interestingly, analysis of TCGA data also revealed a strong 
and significant correlation (Pearson r = 0.49, P = 2.61 × 10–12) 
between TLR9 and MAP3K8 (TPL2) mRNA expression in PDAC 
samples (Supplemental Figure 9B). Cotreatment with TPL2i sig-
nificantly attenuated SN-38–induced p-MEK, p-ERK, and p-RSK, 
and increased poly(ADP-ribose) polymerase (PARP) cleavage in 
PDAC lines (Figure 7E). Gemcitabine-induced p-MEK and p-ERK 
levels and SRE activity were also suppressible with TPL2i (Sup-
plemental Figure 9, C and D), suggesting that induction of MAPK 
activity is not specific to one class of cytotoxic agent. Besides 
the MAPK cascade, the TPL2i additionally suppressed p-p105 in 
SN-38–treated Pa01C cells (Supplemental Figure 9E), making it a 
more broad-spectrum therapeutic agent than the MEK inhibitor 
or the ERK inhibitor in curbing chemotherapy-induced survival 
signaling. PDAC cells cotreated with SN38 and TPL2i showed 
significantly more apoptosis (Supplemental Figure 9, F and G) by 
flow cytometric analysis, and completely lost their clonogenicity, 
an assay that tests emergence of resistant clones (Figure 7F and 
Supplemental Figure 10A). Notably, the combination of TPL2i 
and SN-38 was synergistic in suppressing PDAC cell growth by the 
Loewe additivity model (Supplemental Figure 10B). Accordingly, 
the combination of TPL2i and FIRINOX was significantly more 
efficacious in suppressing in vivo subcutaneous growth of Pa01C 
tumors compared with either treatment alone (Figure 7G and Sup-
plemental Figure 10, C and D), and without incurring noticeable 
toxicities (Supplemental Figure 10E). TPL2i alone was effective in 
significantly suppressing growth of orthotopic KI tumors in syn-
geneic FVB/NJ mice. When combined with FIRINOX, the mean 
tumor burden was seemingly further reduced, with 2 mice show-
ing no evidence of cancer, although the difference between TPL2i 
6A), which we confirmed by IL-1β ELISA of conditioned media 
(CM) collected from these cells (~120-fold higher in KRASG12V- 
expressing cells, Supplemental Figure 7A). Furthermore, analysis 
of oncogenic KRAS signature showed IL1B expression was signifi-
cantly higher in MAP3K8High patients (Figure 6B). These results 
suggest autocrine IL-1β is the driver of IRAK4 and TPL2 activity in 
KRAS-mutant cells. In support, KRASG12V expression upregulated 
p-IRAK4, p-TPL2, p-MEK, and p-ERK levels in HEK T/tH cells, 
but all were dose-dependently reversed by treatment with a neu-
tralizing anti–human IL-1β (anti–hIL-1β) antibody (Figure 6C). CM 
collected from HEK-T/tH KRASG12V cells was able to upregulate 
p-TPL2, p-IRAK4, p-MEK, and p-ERK levels in HEK T/tH cells, 
but the effect was blunted with neutralizing anti–hIL-1β antibody 
(Figure 6D), shRNA knockdown of IL-1R of recipient HEK T/tH 
cells (Supplemental Figure 7, B and C), and completely blocked by 
cotreatment with TPL2i (Figure 6E). In support of these data, CM 
from HEK-T/tH KRASG12V cells stimulated SRE reporter activity of 
HPAC cells by approximately 3-fold (Supplemental Figure 7D) and 
treatment of HEK T/tH, HPAC, and Pa01C cells with recombinant 
hIL-1β upregulated p-IRAK4, p-TPL2, p-MEK, p-ERK, and p-RSK 
(Figure 6F and Supplemental Figure 7E). Knockdown of IL-1R also 
blunted upregulation of p-MEK and p-ERK in HEK-T/tH trans-
fected with KRASG12V or MAP3K8 (TPL2) (Figure 6G), with simi-
lar effects observed in KRAS-mutant Pa01C cells (Supplemental 
Figure 7F). These data establish autocrine IL-1β/IRAK4/TPL2 
signaling as a parallel mechanism, apart from RAF kinases, 
through which KRAS oncoprotein drives MAPK signaling.
We next investigated the mechanism by which KRAS pro-
motes IL-1β production. We treated HEK T/tH KRASG12V cells with 
MEK (trametinib), ERK (ulixertinib), or PI3K (GDC-0941) inhib-
itors and found that both MEK and ERK inhibitors significantly 
abrogated IL-1β production, whereas the PI3Ki had no effect (Sup-
plemental Figure 7G). These data depict a model in which KRAS 
oncoprotein uses the MAPK effectors to promote IL-1β production 
and create an autocrine IL-1β–IL-1R–IRAK4–TPL2–MAPK feed-
forward loop that amplifies MAPK signaling. From TCGA data-
base, elevated IL1B expression associated with poor prognosis in 
PDAC (Figure 6H). The mRNA level of TPL2 (MAP3K8) moder-
ately (r = 0.36) and strongly (r = 0.5) positively correlated with 
IL1B and IL1R1, respectively (Supplemental Figure 8, A and B). In 
KP2 cells, CRISPR knockout of Irak4 led to downregulation of GO 
signatures associated with IL-1, and reexpression of Irak4 (rescue) 
significantly restored these signatures (Supplemental Figure 8, C 
and D). In these gene sets, TPL2 was present in the leading edge as 
a core enrichment in an IRAK4-dependent manner (Supplemen-
tal Figure 8E), again signifying its role in IL-1 and cytokine signal-
ing. Together, these data establish autocrine IL-1R/IRAK4/TPL2 
signaling as an essential mechanism hijacked by KRAS that should 
be therapeutically targeted.
TPL2 inhibition potentiates chemotherapy by curbing MAPK 
and NF-κB activation. Molecularly targeted therapies have been 
ineffective in treating PDAC patients. Therefore, it is unlikely 
that TPL2 inhibition or IRAK4 inhibition alone will be clinically 
effective, and combination regimens will need to be developed. 
Chemo therapy is currently the only effective treatment modality 
for PDAC, but treatment response is neither universal nor durable 
(31, 32). Stress-induced NF-κB and MAPK survival signaling are 
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function mutation. To comprehensively evaluate the impact of the 
E188K mutation, we performed RPPA analysis on 293T cells ecto-
pically expressing vector, and a roughly equal amount of TPL2WT 
or TPL2E188K (Figure 8B). Of all 441 markers analyzed, p-ERK is the 
most differentially upregulated marker in TPL2E188K-expressing cells 
(Figure 8D), validating our findings with immunoblots and reporter 
assay. We also observed significantly increased p-S6, a known sub-
strate of ERK, and p-c-Jun, which has been described as a TPL2 
effector (ref. 30 and Figure 8E). This analysis showed, in a compre-
hensive and unbiased manner, the MEK/ERK cascade to be the pre-
dominant signaling cascade activated by the E188K mutation.
To delineate the molecular mechanism underlying the 
enhanced kinase activity of TPL2E188K, we first compared the half-
lives of TPL2WT and TPL2E188K in 293T cells treated with a protein 
synthesis inhibitor, cycloheximide. Surprisingly, we found that the 
E188K mutation, despite being located within the kinase domain, 
rendered the TPL2 protein more stable (Figure 9A). Supporting 
this finding, immunoprecipitation assay showed that the E188K 
mutation almost completely abolished TPL2 polyubiquitina-
tion, a prerequisite for proteasomal degradation (Figure 9B). To 
evaluate the oncogenicity of TPL2E188K, we obtained Hs695T, a 
BRAFV600E-mutant melanoma cell line that naturally harbors the 
MAP3K8E188K mutation. Sanger sequencing of cDNA from Hs695T 
confirmed a G→A mutation in codon 188 of MAP3K8, which con-
verts glutamate (GAG) to lysine (AAG) (Figure 9C). We therefore 
speculate that TPL2E188K may be an oncoprotein driving MAPK 
activation in this cell line. Supporting this notion, treatment with 
TPL2i suppressed p-ERK and p-MEK (Figure 9D) as well as in vitro 
proliferation and viability of Hs695T cells (Figure 9E and Supple-
mental Figure 11C). Importantly, the BRAF inhibitor PLX4032 
had a modest growth suppressive effect, but when combined 
with TPL2i, it significantly lowered (P < 0.0001) the viability of 
Hs695T (Figure 9F), indicating that both BRAF and MAP3K8 
mutations contribute to MAPK activity in this cell line.
We next determined the effect of mutation at codon 442, 
which resides in the C-terminus, implying disruption of degra-
dation function. We chose to study the R442H mutant because 
it is the most common mutation described in TCGA and more 
potent in inducing SRE and NF-κB reporter activity than WT pro-
tein (Supplemental Figure 11, A and B). Compared with TPL2WT, 
TPL2R442H is more potent in activating MEK, ERK, and RSK (Fig-
ure 10A) when expressed at equivalent levels. As expected, the 
stability of TPL2R442H mutant protein was higher than TPL2WT and 
comparable to C-terminally truncated TPL2 (Figure 10B). Inter-
estingly, other mutations including L444V and R459W also ren-
der TPL2 slightly more stable than the WT form, albeit not to the 
degree imparted by R442H. All these mutations reduce polyubiq-
uitination of TPL2 (Figure 10C), which explains their increased 
stability. The naturally occurring MAP3K8R442H mutation has been 
reported in the ovarian cancer cell line IGROV1 (40). Remark-
ably, short-duration (2 hours) treatment with a very low dose of 
TPL2i (1 μM) completely blocked p-MEK, p-ERK, and p-RSK in 
this cell line to undetectable levels even with high exposure time 
(Figure 10D), suggesting that TPL2 is the dominant driver of 
MAPK activity in this cell line. In support of this, partial knock-
down of TPL2 also reduced MAPK activity in IGROV1 (Figure 
10E). Pharmacologic inhibition or silencing of TPL2 significantly 
and combo arms did not reach statistical significance probably 
due to low mouse number per arm (Figure 7H). These results show 
that targeting TPL2 overcomes genotoxic stress–induced survival 
signaling and enhances the efficacy of chemotherapy.
MAP3K8 point mutations, E188K and R442H, hyperactivate 
MAPK and NF-κB cascades. Aside from being summoned by onco-
genic RAS and genotoxic stress, TPL2 is also spontaneously acti-
vated by genetic mutations. In the basal state, TPL2 protein is 
bound and inhibited by p105 (NF-κB1) and A20-binding inhibitor 
of NF-κB (ABIN-2). Activated IKK complex phosphorylates p105 
and prompts its proteolysis to p50, which releases TPL2 (34). TPL2 
undergoes phosphorylation at residues S400 by IKK and T290 
by an unknown kinase to become fully activated, after which it is 
proteasomally degraded via polyubiquitination at its C-terminus 
(35–37). Therefore, C-terminally truncated TPL2 is more stable 
and potent in activating the MAPK pathway (38). Oncogenic trun-
cations and fusions of MAP3K8 are reported in spitzoid melanomas 
and predict sensitivity to MEK inhibitors in vitro (39). Besides trun-
cations, from TCGA database we noticed several point mutations 
in MAP3K8 across various non-PDAC cancer types that have not 
been characterized. Therefore, we investigated 5 point mutants 
that occur with the highest frequency: E188K, R397H, R442H, 
L444V, and R459W (Figure 8A). Of these mutants, we found 
E188K and R442H to be the most potent in stimulating SRE and 
NF-κB reporter activities (Supplemental Figure 11, A and B), which 
we characterized in further detail. The E188K mutation is detected 
in oligodendroglioma and colon and urothelial carcinoma, where-
as R442 can acquire missense (to H or C) or nonsense mutations in 
colon, ovarian, and gastric cancers, and rhabdoid tumors.
When expressed at the same level as WT, TPL2E188K is mark-
edly more potent in activating MEK, ERK, RSK, and p105 (Figure 
8B), as well as inducing SRE and NF-κB reporter activities (Figure 
8C) in unperturbed 293T cells, clearly showing this is a gain-of-
Figure 5. TPL2 drives both MAPK and NF-κB signaling in PDAC. (A) Gene 
set enrichment plots for patients with high (Z score > 1, n = 22) and low (Z 
score < 1, n = 28) MAP3K8 (TPL2) expression from TCGA Firehose Legacy 
study. (B) Immunoblots of KRAS-mutant human PDAC cell lines treated 
with TPL2 inhibitor (TPL2i) or vehicle (V) for 36 hours in serum-free media. 
(C) Immunoblots of 293T and 293T-KRASG12V cells treated with TPL2i for 24 
hours in serum-free condition. (D) Immunoblots of Pa01C cells treated with 
incremental doses of TPL2i. (E) Immunoblots of PDAC cell lines treated 
with TPL2i. (F) Serum-response element (SRE) reporter assay of HPAC 
cells treated with TPL2i, BRAFi, MEKi, or ERKi. Data show 3 independent 
experiments, each done with triplicate samples. (G) Quantification of soft-
agar colonies formed by PDAC cell lines treated with TPL2i. Data represent 
n = 3 (n = 2 for CFPAC-1) for each cell line. One data point is shown per 
biological replicate, each consisting of 3 technical replicates. P values from 
2-way ANOVA with Dunnett’s multiple-comparisons test. (H) Immunoblots 
of WT or MAP3K8-knockdown HPAC cells. (I) Quantification of HPAC and 
Pa01C cell proliferation after TPL2 knockdown with shRNA (shMAP3K8). 
Each data point is the average of 6 replicates. P values by 2-way ANOVA 
with Dunnett’s multiple-comparisons test. (J) Representative crystal 
violet–stained images of 2D colony formation of TPL2-knockdown HPAC 
and Pa01C cells. (K) Light microscopic images of organoids formed by HPAC 
and Pa01C cells with TPL2 knockdown. Scale bars: 100 μm (full images) and 
25 μm (insets). Graph on right is quantification of number of organoids 
formed in 3 independent wells. P values by 2-way ANOVA with Dunnett’s 
multiple-comparisons test. All data presented as mean ± SEM. ****P < 
0.0001; ***P < 0.0002; *P < 0.0332.
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In this study, we show the autocrine IL-1β–driven IRAK4/TPL2 
axis to be an essential component of KRAS and MAPK signaling. 
Because IRAK4 is typically activated by inflammatory receptors 
IL-1R, TLRs, and TNFR, it is most widely studied as the driver of 
NF-κB activity in immune cells (47). Strikingly, ablation of IRAK4 
completely blocked RAS-induced transformation and tumori-
genicity in both epithelial cells and fibroblasts, as well as PDAC 
cells. These data are in strong agreement with an elegant study 
by Ling et al. showing that ablation of IKKβ, a key downstream 
substrate of IRAK4, completely abolished PDAC development in 
a KRAS/Ink4a mouse model (8). The IL-1R antagonist Anakin-
ra is currently being tested in clinical trials in combination with 
chemotherapy for PDAC (NCT02550327). Downstream of 
IRAK4, we revealed TPL2 as a MAP3K that drives MEK/ERK 
and NF-κB p105 in KRAS-mutant cells independently of the RAF 
kinases. Therefore, TPL2 is a promising therapeutic target that 
controls multiple signaling cascades in KRAS-driven cancers.
Aside from enforcing KRAS autocrine signaling, the IRAK4/
TPL2 axis is further used following genotoxic stress as a survival 
mechanism. Induction of MAPK activity is a well-established 
mechanism that allows cancer cells to endure genotoxic stress 
(48). However, MEK inhibitors fail to potentiate chemotherapy in 
pancreatic cancer (49, 50), suggesting that targeting MAPK alone 
is insufficient, or that compensatory escape mechanisms such 
as enhanced NF-κB activity should be cotargeted. Similarly, in a 
prostate cancer model, addition of an NF-κB pathway inhibitor 
significantly potentiates the antitumor effect of MEK inhibitors 
(51). Here in our study, we found that PDAC cells adapt to che-
motherapy by upregulating TLR9, which signals through IRAK4/
IKK/TPL2 to activate multiple pathways. Therefore, PDAC cells 
use different receptors, IL-1R at baseline and TLR9 during geno-
toxic stress, to engage the same IRAK4/IKK/TPL2 axis for sur-
vival. It is important to keep in mind that since the therapeutic 
spectrum of TPL2i extends beyond MEK/ERK, encompassing the 
NF-κB, JNK, and p38 cascades, all of which have been implicated 
in chemoresistance, TPL2 may be a more promising therapeutic 
target than MEK or ERK when combined with chemotherapy, at 
least in PDAC. In accordance, pharmacologic TPL2 inhibition 
completely blocked chemotherapy-induced MAPK and NF-κB 
activation, resulting in greater apoptosis and tumor suppression in 
vivo (Supplemental Figures 9, 10, and 13).
To the best of our knowledge, our study is the first to report gain-
of-function point mutations of TPL2. Overexpression, C-terminal 
truncations, or fusions of TPL2 have been found in T cell neoplasms, 
melanoma, ovarian, breast, and lung cancers. These mutations are 
associated with RAF inhibitor resistance, and can be targeted with 
MEK inhibitors (39, 41, 52–55). Compared with WT protein, the 
E188K and R442H mutants we studied are more stable and capable 
of hyperactivating both MAPK and NF-κB cascades. Furthermore, 
cancer cell lines naturally harboring these mutations (Hs695T for 
E188K, and IGROV1 for R442H) are highly sensitive to TPL2 inhi-
bition. Importantly, TPL2i significantly suppressed MAPK activity 
and proliferation of BRAFV600E/MAP3K8E188K double-mutant Hs695T 
cells, but not in BRAFV600E/MAP3K8WT BxPc-3 cells, demonstrating 
that MAP3K8E188K is oncogenic.
The crystal structure of the C-terminus of TPL2 has not been 
resolved, and therefore how these mutations conformationally 
decreased the proliferation, colony forming ability, and AI 
growth of IGROV1 (Figure 10, F and G, and Supplemental Figure 
12, A–C), consistent with prior reports (41). Importantly, while 
knockdown of TPL2 markedly crippled the ability of IGROV1 to 
grow into 3D organoids or 2D clones, these growths could only be 
rescued by reexpression of TPL2R442H but not TPL2WT (Figure 10H 
and Supplemental Figure 12D). Overall, these studies are the first 
to our knowledge to describe gain-of-function point mutations of 
MAP3K8 (TPL2) in human cancers, further prompting the need to 
identify these mutations in clinical practice and develop dedicated 
 TPL2 inhibitors for clinical trials.
Discussion
Our present study provides broader understanding of the role of 
IRAK4 and TPL2 in human cancers. Using genetically defined cell 
lines and PDAC as a disease model, we show that KRAS oncop-
rotein uses the MAPK cascade to upregulate IL-1β production, 
leading to autocrine activation of IRAK4 and TPL2, which feeds 
back to escalate MAPK activity and additionally the NF-κB cas-
cade. Following genotoxic stress, PDAC cells upregulate TLR9, 
leading to enhanced utilization of the IRAK4/TPL2 axis to sustain 
survival. Additionally, we characterize what we believe to be novel 
gain-of-function TPL2 mutations that hyperactivate the MAPK 
and NF-κB pathways.
The malignant feats of RAS oncoproteins result from direct 
and indirect signaling mechanisms. RAS oncoproteins can directly 
bind and activate several effectors including the RAF kinases, 
PI3 kinases, RalGEFs, and Tiam1 (2). Through these pathways, 
a plethora of inflammatory chemokines and cytokines including 
IL-6, IL-8, IL-1α/β, and CCL5 are produced, which in an auto-
crine manner trigger the inflammatory JAK/STAT and NF-κB 
cascades (10, 22, 42–46). These secondary events not only help 
propagate tumor progression, but also shield cancer cells from 
therapeutic attacks. For instance, in KRAS-mutant lung cancer, 
TBK1- and IKK-driven CCL5 and IL-6 can activate the JAK/
STAT pathway to confer resistance to MEK inhibitors (42). In 
PDAC, STAT3 activation drives resistance to MEK inhibitors 
(44, 45). Therefore, autocrine/paracrine cytokine signaling pro-
vides equally essential support, in addition to the intrinsic onco-
genic events, that help cancer cells adapt and withstand stress. 
Figure 6. KRAS induces autocrine IL-1β signaling, which activates IRAK4 
and TPL2. (A) qRT-PCR of HEK cells expressing empty vector or KRASG12V. 
Data show 6 replicates from 2 independent experiments. ****P < 0.0001 
by 2-way ANOVA with Dunnett’s multiple-comparisons test. (B) Heat-
map of Hallmark “KRAS signaling up” signature in MAP3K8-high vs. -low 
patients. IL1B is significantly enriched in MAP3K8High patients, shown 
also in box-and-whisker plot on right. Significance tested with unpaired, 
2-sided t test. (C) Immunoblots of HEK-KRASG12V cells treated with anti–
hIL-1β neutralizing antibody for 24 hours. (D) Immunoblots of HEK cells 
incubated with conditioned media (CM) from HEK-KRASG12V cells (called 
“KRASG12V CM”) and anti–hIL-1β neutralizing antibody. (E) Immunoblots 
of HEK cells incubated with KRASG12V CM and TPL2i or vehicle (V) for 16 
hours. (F) Immunoblots of HEK and HPAC cells overexpressing HA epitope–
tagged WT TPL2 stimulated with 100 ng/mL recombinant hIL-1β for the 
indicated duration. (G) Immunoblots of HEK cells expressing KRASG12V, HA 
epitope–tagged WT TPL2, and shIL1R1. (H) Kaplan-Meier curve of PDAC 
TCGA patients with high vs. low IL1B expression. Follow-up censored at 60 
months. All data presented as mean ± SEM.
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and R442H mutants remain sensitive to the TPL2i that we tested. 
TPL2i and RAFi cooperate to curb the growth of Hs695T cells that 
harbor MAP3K8E188K and BRAFV600E mutations, and MAPK activity 
in IGROV1 ovarian cancer cells that harbor only the MAP3K8R442H 
mutation is completely abolished by low-dose TPL2i.
In this study, we demonstrated the in vivo antitumor efficacy 
of TPL2i as a single agent and in combination with chemotherapy. 
Targeting IRAK4 or TPL2 is not expected to have severe side effects 
and none were observed in mice. Irak4-knockout mice are viable and 
have normal lifespan but are immunocompromised (33). Humans 
with inborn IRAK4 deficiency are susceptible to life-threatening 
bacterial infection in early infancy, but with proper antibiotic pro-
phylaxis have survived into adolescence and adulthood (56). The 
IRAK4 inhibitor CA-4948 is now in clinical trial (NCT03328078) for 
patients with refractory hematologic malignancies, and is found to 
be rather well tolerated, with 23% of patients developing grade 1–2 
neutropenia (57). Similarly, Map3k8-knockout mice do not exhibit 
obvious phenotypic defects, and have normal bone marrow but are 
impaired in MEK/ERK activation and TNF-α production following 
LPS challenge (58). To date, no TPL2i has been developed and tested 
in clinical trials. We argue that TPL2 is a more versatile kinase that 
controls multiple oncogenic pathways besides MEK/ERK, and 
therefore development of a dedicated TPL2i is needed especially 
for KRAS- or MAP3K8-mutant cancers.
In conclusion, our study comprehensively describes an essen-
tial role of IRAK4 and TPL2 in oncogenic RAS signaling, using 
PDAC as a disease model. Mechanistically, we show that the 
IRAK4/TPL2 axis is differentially engaged in the basal state versus 
during genotoxic stress by different upstream receptors. We show 
that TPL2 inhibition synergistically sensitizes PDAC to chemo-
therapy in in vivo models, which we propose is a potentially novel 
therapeutic strategy. Finally, we characterize 2 gain-of-function 
mutations of MAP3K8 (TPL2) in melanoma and ovarian cancer, 
which complement other studies describing overexpression, trun-
cations, or fusion of MAP3K8 (TPL2) as being oncogenic. Overall, 
our study urges development of dedicated TPL2is and detection of 
MAP3K8 (TPL2) mutations for cancer patients.
Methods
Additional methods description can be found in Supplemental 
Methods.
Cell lines. All cell lines including HPNE, HPNE-KRASG12D, HPAC, 
and Hs695T were obtained from ATCC, which performed its own 
authentication by short tandem repeat DNA profiling. IGROV1 cells 
were a gift from Katherine Fuh (Washington University, St. Louis, Mis-
souri, USA), originated from the NCI-60 panel (59) and not further 
authenticated. The HEK T/tH cell line was a gift from Christopher 
Counter (Duke University, Durham, North Carolina, USA) and previ-
ously published (60). The KP2 cell line was a gift from David DeNardo 
(Washington University) and authenticated by whole-exome sequenc-
ing (61). MEFs were isolated from WT or IRAK4-null mice, as described 
previously (62). The patient-derived cell lines Pa01C, Pa02C, Pa03C, 
Pa04C, Pa14C, and Pa16C were a gift from Channing J. Der (University 
of North Carolina, Chapel Hill, North Carolina, USA) and have been 
described previously (63). All cell lines were cultured in DMEM supple-
mented with 10% fetal bovine serum and 1% penicillin/streptomycin 
except IGROV1 and Hs695T, which were cultured in RPMI-1640 and 
alter the entire protein is unclear. It has been suggested that the 
C-terminus of TPL2 negatively regulates TPL2 kinase activity via 
intramolecular interaction with its kinase domain (38). In addi-
tion, the C-terminus of TPL2, upon IKK-dependent phosphoryla-
tion of S400 and S443, binds to the 14-3-3 complex that stabilizes 
TPL2 and increases its kinase activity toward MEK1, possibly by 
relieving the kinase-inhibitory interaction between the C-termi-
nus and kinase domain (35). The R442H mutation may impact 
TPL2 binding with 14-3-3, resulting in the increased stability and 
increased MEK and ERK activation that we observed in our exper-
iments. On the other hand, R442 is part of a conserved MAPK rec-
ognition motif (KRQRSLYIDL) present on TPL2 (39). This raises 
the possibility that mutation of Arg to His at this residue may alter 
TPL2’s binding affinity and/or specificity for substrates, although 
detailed additional work is required to prove this. The mechanism 
by which the E188K mutation stabilizes the protein is intriguing, 
as this residue is located within the kinase domain which is distant 
from the C-terminal degron. It is possible that this E188K muta-
tion enhances the intrinsic kinase activity in addition to disrupt-
ing its degradation, but this will require resolution of the entire 
TPL2 protein structure. Furthermore, the mechanism including 
the E3 ligase that governs the degradation of TPL2 is unknown 
and should be investigated. This is especially important because 
our PDAC TMA showed p-IRAK4 level to be strongly associated 
with high TPL2 protein level, which in turn is associated with poor 
prognosis. Therefore, we speculate that high IRAK4 activity may 
protect TPL2 from degradation, although the detailed mechanism 
remains to be determined. Whether upstream TLR/IL-1R activa-
tion is required for the enhanced activity of the E188K or R442H 
mutant is uncertain. However, this is unlikely because these 
mutants exhibit markedly enhanced activity in unperturbed 293T 
cells compared with the WT counterpart. Importantly, both E188K 
Figure 7. TPL2 inhibition potentiates chemotherapy by curbing MAPK 
and NF-κB activation. (A) Immunoblots of 2 PDAC cell lines overex-
pressing HA epitope–tagged TPL2 WT treated for 16 hours with different 
chemotherapy agents (10 μM each). (B and C) Quantification of mRNA 
transcript levels for multiple genes in 3 PDAC cell lines treated with 
vehicle, gemcitabine-paclitaxel (Gem-PTX), or FIRINOX (10 μM each of 
5-FU, SN-38, and oxaliplatin). (D) Duolink proximity ligation assay (PLA) 
identifying interaction between p-IRAK4 and TLR9 in 3 PDAC cell lines 
treated with 10 μM SN-38 for 16 hours. Six ×400 magnification fields per 
condition were analyzed. Scale bars: 10 μm. (E) Immunoblots of 3 PDAC 
cell lines treated with TPL2i, SN-38, or their combination for 16 hours. 
FL, full length; V, vehicle. (F) 2D crystal violet clonogenic colony-forming 
assays of 3 PDAC cell lines treated with TPL2i, SN-38 (2.5 nM, 5 nM, and 
10 nM), or their combination in a dose matrix for 3 to 4 weeks. Data show 
1 independent experiment out of ≥3 per cell line. (G) Tumor volume curves 
for patient-derived Pa01C PDAC cells implanted subcutaneously into nude 
mice followed by treatment with TPL2i, FIRINOX, or combination therapy. 
Data represent 10 independent tumors (n = 10) for each drug treatment 
group and 8 independent tumors (n = 8) for vehicle-treated group. P value 
from 2-way ANOVA followed by Tukey’s multiple-comparisons test. One 
outlier was removed by Grubb’s test, α = 0.01. (H) Graph depicting final 
tumor weight (final pancreas weight – 0.1 g [i.e., normal pancreas weight]) 
after orthoptic injection of murine KI cells and treatment as indicated for 
14 days. Images of ex vivo and in vivo tumors detected by ultrasound along 
with tumor volume are shown on right. P values from 1-way ANOVA with 
Tukey’s multiple-comparisons test. All data presented as mean ± SEM. 
****P < 0.0001; ***P < 0.0002; **P < 0.0021; *P < 0.0332.
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Figure 8. E188K mutation in MAP3K8/TPL2 is a gain-of-function mutation. (A) Lollipop plot adapted from CBioPortal.org (as of August 2019) identifying 
mutations in MAP3K8/TPL2. (B) Immunoblots of 293T cells transfected with empty expression vector (EV, control) or vector encoding HA epitope–tagged 
WT TPL2 or TPL2 E188K for 48 hours. (C) Relative serum-response element (SRE) activity and NF-κB reporter activity in 293T cells transfected as in B. 
Data are from 2 independent experiments. ****P < 0.0001 by 2-way ANOVA followed by Tukey’s multiple-comparisons test. (D) Heatmap representing rel-
ative expression in log2 units of proteins evaluated by reverse-phase protein array (RPPA) of 293T cells transfected with empty vector (EV, control) or vector 
encoding HA-tagged WT TPL2 or TPL2 E188K in duplicate (n = 2) for 48 hours. (E) Relative abundance (in log2 units) of the top 15 upregulated targets in 
RPPA shown in D. p-ERK (in bold text) is the top hit and significantly upregulated targets are indicated with P values from 2-way ANOVA with Tukey’s 
multiple-comparisons test. All data presented as mean ± SEM.
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were treated with vehicle. Tumor volume was calculated as width2 × 
(length × 0.5). Tumors were measured and mice were weighed 3 days 
per week. For orthotopic implantation, murine KI PDAC cells were 
injected into the pancreas of 7-week-old female FVB/NJ mice (Jackson 
Laboratory), as previously described (64). Six days after implantation, 
treatment with vehicle, FIRINOX (same dose as above), or TPL2i (30 
mg/kg) was initiated for 14 days, at which time all mice were sacrificed. 
In vivo tumor progression was monitored using ultrasound (VScan, GE 
Healthcare) with final day representative tumor images shown.
Statistics. All results, when applicable, are expressed as mean ± 
SEM. Statistical analysis was performed using GraphPad Prism v7 or 
v8 software. Unpaired, 2-tailed (2-sided) Student’s t tests were used 
to compare 2 groups when appropriate. For multiple groups, 1-way or 
2-way ANOVA with appropriate post hoc test was used. In instances 
MEM, respectively, with nonessential amino acids along with other sup-
plements stated above. Mycoplasma testing was performed annually 
using a MycoSEQ Detection kit (Applied Biosystems). All lines were 
used for fewer than 6 months after receipt or resuscitation from cryo-
preservation. For all drug treatments, when applicable, a concentration 
of 0 (zero) is treatment with vehicle, DMSO.
In vivo tumorigenesis assays. For subcutaneous xenograft, approxi-
mately 5 million cells per flank were implanted into 6-week-old athy-
mic nude mice (NU/J, Jackson Laboratory). When applicable, treat-
ment with drug compound was initiated when tumors were palpable. 
FIRINOX (25 mg/kg 5-FU, 17.5 mg/kg irinotecan, and 3.35 mg/kg 
oxaliplatin) was administered via intraperitoneal injection weekly in 
50 μL PBS. TPL2i was administered by intraperitoneal injection at 10 
mg/kg in 40 μL DMSO, 5 days per week. Mice in the control group 
Figure 9. E188K mutation stabilizes TPL2 protein. (A) Immunoblots of HEK T/tH cells stably expressing HA epitope–tagged WT TPL2 or TPL2 E188K 
treated with 10 μg/mL cycloheximide (CHX). Table below shows half-life (t1/2) of WT TPL2 and TPL2 E188K protein calculated by measuring HA-TPL2 
band intensities, normalizing to t0 and performing 1-phase exponential decay. Data represent 1 of 3 independent experiments showing similar results. (B) 
Immunoprecipitation of HA epitope–tagged WT TPL2 or TPL2 E188K treated with 10 μM MG132 (proteasome inhibitor) and immunoblotted as indicated. 
(C) Sanger sequencing peaks of MAP3K8 (TPL2) locus in Hs695T. Arrow indicates the naturally occurring missense point mutation responsible for the 
Glu→Lys substitution at codon 188 (E188K) in TPL2 in the Hs695T cell line. (D) Immunoblot of Hs695T cells treated with TPL2i or vehicle (V) for 24 hours in 
10% serum–containing media. (E) Proliferation of Hs695T cells treated with TPL2i. P values from 2-way ANOVA with Dunnett’s multiple-comparisons test. 
(F) Viability of Hs695T cells treated with PLX4032 (BRAFi) alone or in combination with 2 different concentrations of TPL2i. Graph on right depicts GI50 of 
PLX4032 in log10 units. Data represent 10 replicates from 4 independent experiments. P values are from 1-way ANOVA with Dunnett’s multiple-compari-
sons test. All data presented as mean ± SEM. ****P < 0.0001; ***P < 0.0002; **P < 0.0021.
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Figure 10. R442H is a gain-of-function mutation that curtails 
proteasomal degradation of TPL2. (A) Immunoblots of 293T 
cells transiently transfected with empty vector (EV), or vector 
encoding HA epitope–tagged WT TPL2 or TPL2 R442H for 48 
hours. On right is quantification of p-ERK band intensities 
for WT TPL2 and TPL2 R442H samples from immunoblots on 
left. Data represent 2 independent experiments. P values from 
2-way ANOVA with Holm-Šidák multiple-comparisons test. (B) 
Immunoblots of HEK T/tH cells stably expressing vector encoding 
WT TPL2 or TPL2 R442H and treated with 10 μg/mL cyclohexi-
mide (CHX) for indicated durations. Table below states half-life 
(t1/2) of TPL2 WT and mutant proteins calculated by measuring 
HA-TPL2 band intensities, normalizing to t0 and performing 
1-phase exponential decay analysis as shown in graph at the 
bottom. Experiment was performed 3 times and 1 set of data 
is shown. (C) Immunoblots of HEK T/tH cells stably expressing 
empty vector or HA epitope–tagged TPL2 mutants treated with 
10 μM MG132 (proteasome inhibitor) for 4 hours. One of 2 or more 
independent experiments is shown. C-terminally truncated TPL2 
(ΔC-term) is used as positive control. Poly-Ub, polyubiquitinated. 
(D) Immunoblots of IGROV1 cells serum starved for 24 hours and 
treated with TPL2i for 2 hours. (E) Immunoblots of IGROV1 cells 
after shRNA-mediated TPL2 depletion. (F and G) Proliferation 
of IGROV1 cells treated with TPL2i and after shRNA-mediated 
TPL2 depletion, respectively. P values from 2-way ANOVA with 
Dunnett’s multiple-comparisons test. (H) 3D organoid growth of 
IGROV1 cells after shRNA-mediated TPL2 depletion and rescue 
with either WT TPL2 or R442H mutant. Organoids were counted 
from 4 independent transfected wells per condition. Scale bars: 
100 μm. P values from 1-way ANOVA with Dunnett’s multiple- 
comparisons test. All data presented as mean ± SEM. ****P < 
0.0001; ***P < 0.0002; **P < 0.0021; *P < 0.0332.
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analysis. NK performed Western blotting to evaluate degradation 
of TPL2 C-terminal mutants. DZ, HJ, YC, and LL each contributed 
one or more panels of data in the manuscript, including DuoLink 
assay, soft agar, and mouse experiments with IRAK4-knockout 
cells, flow cytometry, and IHC staining, respectively. LL, QW, 
KS, and PMG provided technical assistance. AWG generated the 
human PDAC TMA. KHL assigned author responsibilities, super-
vised, provided funding, and administered the project.
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